267 related articles for article (PubMed ID: 24572100)
1. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.
Yip V; Palma E; Tesar DB; Mundo EE; Bumbaca D; Torres EK; Reyes NA; Shen BQ; Fielder PJ; Prabhu S; Khawli LA; Boswell CA
MAbs; 2014; 6(3):689-96. PubMed ID: 24572100
[TBL] [Abstract][Full Text] [Related]
2. The effect of the neonatal Fc receptor on human IgG biodistribution in mice.
Chen N; Wang W; Fauty S; Fang Y; Hamuro L; Hussain A; Prueksaritanont T
MAbs; 2014; 6(2):502-8. PubMed ID: 24492305
[TBL] [Abstract][Full Text] [Related]
3. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
4. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
5. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
Proetzel G; Roopenian DC
Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
[TBL] [Abstract][Full Text] [Related]
6. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Jiang W; Wroblewski VJ
Drug Metab Dispos; 2007 Jan; 35(1):86-94. PubMed ID: 17050651
[TBL] [Abstract][Full Text] [Related]
7. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
[TBL] [Abstract][Full Text] [Related]
8. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
9. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
10. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ
J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice.
Deng R; Meng YG; Hoyte K; Lutman J; Lu Y; Iyer S; DeForge LE; Theil FP; Fielder PJ; Prabhu S
MAbs; 2012; 4(1):101-9. PubMed ID: 22327433
[TBL] [Abstract][Full Text] [Related]
13. Reduced elimination of IgG antibodies by engineering the variable region.
Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
[TBL] [Abstract][Full Text] [Related]
14. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
[TBL] [Abstract][Full Text] [Related]
15. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
16. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
17. FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Cines DB; Zaitsev S; Rauova L; Rux AH; Stepanova V; Krishnaswamy S; Sarkar A; Kowalska MA; Zhao G; Mast AE; Blumberg LJ; McCrae KR; Poncz M; Hubbard JJ; Pyzik M; Blumberg RS
Blood; 2020 Jun; 135(23):2085-2093. PubMed ID: 32187355
[TBL] [Abstract][Full Text] [Related]
18. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
Ng CM; Fielder PJ; Jin J; Deng R
AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
[TBL] [Abstract][Full Text] [Related]
20. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
